Cost Study of Hydroprogesterone and Glybenclamide

1346. SHRIMATI KAILASHPATI:
SHRIMATI PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1268 given in the Rajya Sabha on 21st May, 1990 and state:

(a) whether it is a fact that Standing Committee has taken a decision on Hydroprogesterone and Glybenclamide;

(b) if so, what are the details thereof;

(c) when was the recommendation of BICP on cost study of Sulphamoxole received;

(d) whether it is a fact that cost study has not been made on factual data; and

(e) if so, what are the details thereof?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) Recommendation of the Standing Committee with regard to Glybenclamide is under the consideration of the Government. Hydroprogesterone is still under examination by the Standing Committee.

(c) to (e) The recommendations of the Bureau of Industrial Costs and Prices on the fair price of Sulphamoxole were received in June, 1990 and after examination of the report some further details were called from the BICP. These have been received recently. While taking a view on the findings contained in the BICP report all the aspects referred to would be gone into.

Revision of Prices of Analgin based Formulations

1347. SHRIMATI KAILASHPATI : Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what are the basis followed in revising the price of Analgin based formulations;

(b) what was the earlier price of each and what is their revised price;

(c) whether it is a fact that the criteria has been changed;

(d) if so, what are the reasons therefor;

(e) whether it is also a fact that reduction in price is not even *pro rata* to the reduction in the bulk drug price; and

(f) what steps have been taken to rectify the situation and to fix the responsibility?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) to (e) Consequent upon the decrease in the price of bulk drug Analgin, the prices of formulations based on Analgin have been fixed, *suo moto*. As per present practice, while fixing the prices of formulations, 8% incidental charges which covers sales tax, octroi etc. are allowed if the formulation happens to be a leader pack or the bulk drug involved therein is not manufactured by the formulator itself. The ceiling prices of formulations based on bulk drug Analgin has accordingly been fixed, details of which are given in the annexed Statement. (*See* below)

(f) Since the prices have been fixed in accordance with the procedure being followed presently, question does not arise.